2′-Deoxy-4′-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants

International Journal of Biochemistry and Cell Biology

Volumn 40, Issue 11, 2008, Pages 2410-2420

  Kawamoto, Atsushi ^a   Kodama, Eiichi ^a   Sarafianos, Stefan G ^b   Sakagami, Yasuko ^a   Kohgo, Satoru ^c   Kitano, Kenji ^c   Ashida, Noriyuki ^c   Iwai, Yuko ^c   Hayakawa, Hiroyuki ^c   Nakata, Hirotomo ^d,e   Mitsuya, Hiroaki ^d,e   Arnold, Eddy ^f   Matsuoka, Masao ^a  

^a KYOTO UNIVERSITY   (Japan)

^b University of Missouri   (United States)

^c YAMASA CORPORATION   (Japan)

^d KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

^e HIV   (United States)

^f RUTGERS UNIVERSITY   (United States)

Author keywords

Human immunodeficiency virus; Resistance; Reverse transcriptase inhibitor

Indexed keywords

2' DEOXYCYTIDINE KINASE; 2'DEOXY 4 C ETHYNYL 2 FLUOROADENOSINE; ADENOSINE DEAMINASE; ADENOSINE DERIVATIVE; DEOXYCYTIDINE KINASE; UNCLASSIFIED DRUG; 2' DEOXY 4' C ETHYNYL 2 FLUOROADENOSINE; 2'-DEOXY-4'-C-ETHYNYL-2-FLUOROADENOSINE; DEOXYADENOSINE DERIVATIVE; RNA DIRECTED DNA POLYMERASE;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENCY; DRUG SENSITIVITY; ENZYME DEGRADATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOLECULAR MODEL; PROTEIN PHOSPHORYLATION; VIRUS REPLICATION; ANIMAL; CELL LINE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; ENZYMOLOGY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; MULTIDRUG RESISTANCE;

ARA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

ANIMALS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CELL LINE; DEOXYADENOSINES; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, MULTIPLE, VIRAL; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; VIRUS REPLICATION;

EID: 48349089930     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biocel.2008.04.007     Document Type: Article

References (41)

1. Back N.K., Nijhuis M., Keulen W., Boucher C.A., Oude Essink B.O., van Kuilenburg A.B., et al. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J 15 15 (1996) 4040-4049
2. Bethell R., De Muys J., Lippens J., Richard A., Hamelin B., Ren C., et al. In vitro interactions between apricitabine and other deoxycytidine analogues. Antimicrob Agents Chemother 51 8 (2007) 2948-2953
3. Bhalla K.N., Li G.R., Grant S., Cole J.T., MacLaughlin W.W., and Volsky D.J. The effect in vitro of 2′-deoxycytidine on the metabolism and cytotoxicity of 2′,3′-dideoxycytidine. AIDS 4 5 (1990) 427-431
4. Boyer P.L., Sarafianos S.G., Arnold E., and Hughes S.H. Nucleoside analog resistance caused by insertions in the fingers of human immunodeficiency virus type 1 reverse transcriptase involves ATP-mediated excision. J Virol 76 18 (2002) 9143-9151
5. Carson D.A., Wasson D.B., Kaye J., Ullman B., Martin Jr. D.W., Robins R.K., et al. Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo. Proc Natl Acad Sci USA 77 11 (1980) 6865-6869
6. De Clercq E. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Antiviral Res 38 3 (1998) 153-179
7. Deval J., Selmi B., Boretto J., Egloff M.P., Guerreiro C., Sarfati S., et al. The molecular mechanism of multidrug resistance by the Q151M human immunodeficiency virus type 1 reverse transcriptase and its suppression using alpha-boranophosphate nucleotide analogues. J Biol Chem 277 44 (2002) 42097-42104
8. Dutschman G.E., Grill S.P., Gullen E.A., Haraguchi K., Takeda S., Tanaka H., et al. Novel 4′-substituted stavudine analog with improved anti-human immunodeficiency virus activity and decreased cytotoxicity. Antimicrob Agents Chemother 48 5 (2004) 1640-1646
9. Furman P.A., Fyfe J.A., St Clair M.H., Weinhold K., Rideout J.L., Freeman G.A., et al. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci USA 83 21 (1986) 8333-8337
10. Gotte M., Arion D., Parniak M.A., and Wainberg M.A. The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis. J Virol 74 8 (2000) 3579-3585
11. Haraguchi K., Takeda S., Tanaka H., Nitanda T., Baba M., Dutschman G.E., et al. Synthesis of a highly active new anti-HIV agent 2′,3′-didehydro-3′-deoxy-4′-ethynylthymidine. Bioorg Med Chem Lett 13 21 (2003) 3775-3777
12. Huang H., Chopra R., Verdine G.L., and Harrison S.C. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science 282 5394 (1998) 1669-1675
13. Jeang K.T., Chun R., Lin N.H., Gatignol A., Glabe C.G., and Fan H. In vitro and in vivo binding of human immunodeficiency virus type 1 Tat protein and Sp1 transcription factor. J Virol 67 10 (1993) 6224-6233
14. Kajiwara K., Kodama E., and Matsuoka M. A novel colorimetric assay for CXCR4 and CCR5 tropic human immunodeficiency viruses. Antivir Chem Chemother 17 4 (2006) 215-223
15. Kimpton J., and Emerman M. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J Virol 66 4 (1992) 2232-2239
16. Kodama E.I., Kohgo S., Kitano K., Machida H., Gatanaga H., Shigeta S., et al. 4′-Ethynyl nucleoside analogs: potent inhibitors of multidrug-resistant human immunodeficiency virus variants in vitro. Antimicrob Agents Chemother 45 5 (2001) 1539-1546
17. Kohgo S., Yamada K., Kitano K., Iwai Y., Sakata S., Ashida N., et al. Design, efficient synthesis, and anti-HIV activity of 4′-C-cyano- and 4′-C-ethynyl-2′-deoxy purine nucleosides. Nucleosides Nucleotides Nucleic Acids 23 4 (2004) 671-690
18. Kosalaraksa P., Kavlick M.F., Maroun V., Le R., and Mitsuya H. Comparative fitness of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 (HIV-1) in an In vitro competitive HIV-1 replication assay. J Virol 73 7 (1999) 5356-5363
19. Larder B.A., Kemp S.D., and Harrigan P.R. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269 5224 (1995) 696-699
20. Little S.J., Holte S., Routy J.P., Daar E.S., Markowitz M., Collier A.C., et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 347 6 (2002) 385-394
21. Martin J.L., Wilson J.E., Haynes R.L., and Furman P.A. Mechanism of resistance of human immunodeficiency virus type 1 to 2′,3′-dideoxyinosine. Proc Natl Acad Sci USA 90 13 (1993) 6135-6139
22. Meyer P.R., Matsuura S.E., Mian A.M., So A.G., and Scott W.A. A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Mol Cell 4 1 (1999) 35-43
23. Mitsuya H., Weinhold K.J., Furman P.A., St Clair M.H., Lehrman S.N., Gallo R.C., et al. 3′-Azido-3′-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci USA 82 20 (1985) 7096-7100
24. Miyake H., Iizawa Y., and Baba M. Novel reporter T-cell line highly susceptible to both CCR5- and CXCR4-using human immunodeficiency virus type 1 and its application to drug susceptibility tests. J Clin Microbiol 41 6 (2003) 2515-2521
25. Nakata H., Amano M., Koh Y., Kodama E., Yang G., Bailey C.M., et al. Activity against Human Immunodeficiency Virus Type 1, intracellular metabolism, and effects on human DNA polymerases of 4′-ethynyl-2-fluoro-2′-deoxyadenosine. Antimicrob Agents Chemother 51 8 (2007) 2701-2708
26. Nameki D., Kodama E., Ikeuchi M., Mabuchi N., Otaka A., Tamamura H., et al. Mutations conferring resistance to human immunodeficiency virus type 1 fusion inhibitors are restricted by gp41 and Rev-responsive element functions. J Virol 79 2 (2005) 764-770
27. Nitanda T., Wang X., Kumamoto H., Haraguchi K., Tanaka H., Cheng Y.C., et al. Anti-human immunodeficiency virus type 1 activity and resistance profile of 2′,3′-didehydro-3′-deoxy-4′-ethynylthymidine in vitro. Antimicrob Agents Chemother 49 8 (2005) 3355-3360
28. Obata T., Endo Y., Tanaka M., Uchida H., Matsuda A., and Sasaki T. Deletion mutants of human deoxycytidine kinase mRNA in cells resistant to antitumor cytosine nucleosides. Jpn J Cancer Res 92 7 (2001) 793-798
29. Ohrui H. 2′-Deoxy-4′-C-ethynyl-2-fluoroadenosine, a nucleoside reverse transcriptase inhibitor, is highly potent against all human immunodeficiency viruses type 1 and has low toxicity. Chem Rec 6 3 (2006) 133-143
30. Palella Jr. F.J., Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338 13 (1998) 853-860
31. Sabini E., Ort S., Monnerjahn C., Konrad M., and Lavie A. Structure of human dCK suggests strategies to improve anticancer and antiviral therapy. Nat Struct Biol 10 7 (2003) 513-519
32. Sarafianos S.G., Das K., Clark Jr. A.D., Ding J., Boyer P.L., Hughes S.H., et al. Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids. Proc Natl Acad Sci USA 96 18 (1999) 10027-10032
33. Selmi B., Boretto J., Sarfati S.R., Guerreiro C., and Canard B. Mechanism-based suppression of dideoxynucleotide resistance by K65R human immunodeficiency virus reverse transcriptase using an alpha-boranophosphate nucleoside analogue. J Biol Chem 276 51 (2001) 48466-48472
34. Shirasaka T., Kavlick M.F., Ueno T., Gao W.Y., Kojima E., Alcaide M.L., et al. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc Natl Acad Sci USA 92 6 (1995) 2398-2402
35. Srinivas R.V., and Fridland A. Antiviral activities of 9-R-2-phosphonomethoxypropyl adenine (PMPA) and bis(isopropyloxymethylcarbonyl)PMPA against various drug-resistant human immunodeficiency virus strains. Antimicrob Agents Chemother 42 6 (1998) 1484-1487
36. Starnes M.C., and Cheng Y.C. Cellular metabolism of 2′,3′-dideoxycytidine, a compound active against human immunodeficiency virus in vitro. J Biol Chem 262 3 (1987) 988-991
37. Tuske S., Sarafianos S.G., Clark Jr. A.D., Ding J., Naeger L.K., White K.L., et al. Structures of HIV-1 RT-DNA complexes before and after incorporation of the anti-AIDS drug tenofovir. Nat Struct Mol Biol 11 5 (2004) 469-474
38. Wainberg M.A., Drosopoulos W.C., Salomon H., Hsu M., Borkow G., Parniak M., et al. Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase. Science 271 5253 (1996) 1282-1285
39. Weiner M.P., Costa G.L., Schoettlin W., Cline J., Mathur E., and Bauer J.C. Site-directed mutagenesis of double-stranded DNA by the polymerase chain reaction. Gene 151 1-2 (1994) 119-123
40. Winters M.A., Coolley K.L., Girard Y.A., Levee D.J., Hamdan H., Shafer R.W., et al. A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. J Clin Invest 102 10 (1998) 1769-1775
41. Yoshimura K., Feldman R., Kodama E., Kavlick M.F., Qiu Y.L., Zemlicka J., et al. In vitro induction of human immunodeficiency virus type 1 variants resistant to phosphoralaninate prodrugs of Z-methylenecyclopropane nucleoside analogues. Antimicrob Agents Chemother 43 10 (1999) 2479-2483